New cocktail of drugs shows promise for tough pancreatic cancer
NCT ID NCT05014776
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of four drugs (tadalafil, pembrolizumab, ipilimumab, and CRS-207) in 17 people with advanced pancreatic cancer that had worsened after at least one round of chemotherapy. The goal was to see if the combination was safe and could shrink tumors. The approach aims to boost the immune system to fight the cancer, but this is not a cure and ongoing management is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?